Efficacy of Antibody Cocktail Drug in COVID-19 Positive Patients: A Retrospective Single-centered Study

Efficacy of Antibody Cocktail Drug in COVID-19 Positive Patients: A Retrospective Single-centered Study

Introduction: Neutralising monoclonal antibodies (mABs) have been proposed and developed for the treatment of Coronavirus Disease-2019 (COVID-19) patients with mild to moderate diseases and to prevent further progression. The combination of Casirivimab and Imdevimab blocks the entry of virus into ce...

Full description

Bibliographic Details
Main Authors:	Manoranjan Dash, Nursingha Charan Dash, Arun Kumar, Smrutirekha Swain, Swetaleena Ashe, Jyoti Patnaik
Format:	Article
Language:	English
Published:	JCDR Research and Publications Private Limited 2023-02-01
Series:	Journal of Clinical and Diagnostic Research
Subjects:	casirivimab clinical profile imdevimab monoclonal antibodies
Online Access:	https://jcdr.net/articles/PDF/17392/59143_CE[Ra1]new_F(IS)_PF1(AG_OM)_PFA(SS)_PB(AG_SS)_PN(SS).pdf

Similar Items

An initial experience with antibody cocktail CASIRIVIMAB and IMDEVIMAB in a center of excellence: A retrospective case series of 3 patients and literature review
by: P Amal Johnson, et al.
Published: (2021-01-01)

Casirivimab and imdevimab as investigational monoclonal antibodies for COVID-19 patients – review of the literature
by: Reka Gabriela, et al.
Published: (2021-09-01)

Antibody Cocktail in Moderate to Severe COVID-19 Infection: A Series of 10 Cases
by: Rohit Hanmanta Bhandari, et al.
Published: (2022-06-01)

The impact of casirivimab-imdevimab antibody cocktail in patients amidst and post COVID 19 treatment: A retro-prospective comparative study in India
by: Aneesh Puthiyedath Joy, et al.
Published: (2022-03-01)

First Case of COVID-19 Treated with Monoclonal Anti-Spike Antibodies in a Patient with Cystic Fibrosis in Romania
by: Iustina Violeta Stan, et al.
Published: (2022-01-01)

Emergency department implementation of monoclonal antibody infusion for the treatment of coronavirus disease 2019: A template for rapid deployment
by: Thomas J. Woltemate, et al.
Published: (2021-10-01)

The effect of casirivimab with imdevimab on disease progression in nonsevere COVID‐19 patients in a single hospital in Japan
by: Junpei Komagamine, et al.
Published: (2022-05-01)

Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern
by: Fulvia Mazzaferri, et al.
Published: (2022-11-01)

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19
by: Flonza Isa, et al.
Published: (2022-09-01)

Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital
by: Judith Pannier, et al.
Published: (2023-02-01)

SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab
by: Martin Heller, et al.
Published: (2023-04-01)

Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies
by: Juan C. Almagro, et al.
Published: (2022-08-01)

Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study
by: Marina S. Lebedkina, et al.
Published: (2023-08-01)

Current Effective Therapeutics in Management of COVID-19
by: Kavya Atluri, et al.
Published: (2022-07-01)

Efficacy and safety of casirivimab-imdevimab combination on COVID-19 patients: A systematic review and meta-analysis randomized controlled trial
by: Imam Adi Wicaksono, et al.
Published: (2023-12-01)

Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological Efficacy
by: Valentine Marie Ferré, et al.
Published: (2022-10-01)

Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies
by: Andrea T. Hooper, et al.
Published: (2022-12-01)

Neutralizing Antibody Therapeutics for COVID-19
by: Aeron C. Hurt, et al.
Published: (2021-04-01)

Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab
by: Laura Ballotta, et al.
Published: (2022-09-01)

Successful treatment of persistent and severe SARS‐CoV‐2 infection in a high‐risk chronic lymphocytic leukemia patient using Ronapreve™ antibodies
by: Fernanda Braga Seganfredo, et al.
Published: (2022-11-01)

Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients
by: Hegazy Sahar K., et al.
Published: (2023-08-01)

Waning Humoral Immune Response to SARS-CoV-2 Vaccination with Symptomatic Infection after Initiation of Anti-CD20 Treatment in a Patient with Multiple Sclerosis
by: Robert Hoepner, et al.
Published: (2022-03-01)

Clinical study to compare the efficacy and safety of casirivimab & imdevimab, remdesivir, and favipravir in hospitalized COVID-19 patients
by: Sahar K. Hegazy, et al.
Published: (2023-06-01)

Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19
by: Valentina Mazzotta, et al.
Published: (2022-04-01)

Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant
by: Gaetano Cicchitto, et al.
Published: (2022-03-01)

Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia
by: Emanuele Palomba, et al.
Published: (2021-09-01)

Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1–August 20, 2021): a retrospective observational monocentric study
by: Yi Guo, et al.
Published: (2022-07-01)

Effect of Casirivimab/Imdevimab Treatment on Serum Type I Interferon Levels in SARS-CoV-2 Infection
by: Kentaro Nagaoka, et al.
Published: (2022-06-01)

REGEN-COV and COVID-19, update on the drug profile and FDA status: A mini-review and bibliometric study
by: Saeid Mezail Mawazi, et al.
Published: (2022-03-01)

Annular lichenoid eruption following treatment with casirivimab/imdevimab for COVID-19
by: Netana H. Markovitz, MD, et al.
Published: (2022-09-01)

Clinical Management of COVID-19: A Review of Pharmacological Treatment Options
by: Ashli M. Heustess, et al.
Published: (2021-05-01)

Neutralizing monoclonal antibodies against SARS-CoV-2 for COVID-19 pneumonia in a rituximab treated patient with systemic sclerosis—A case report and literature review
by: Melek Yalcin Mutlu, et al.
Published: (2022-08-01)

Development and validation of a prediction score for failure to casirivimab/imdevimab in hospitalized patients with COVID-19 pneumonia
by: Alessandro Cozzi-Lepri, et al.
Published: (2024-03-01)

Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy
by: Daniele Focosi, et al.
Published: (2022-07-01)

Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series
by: Göran Ramin Boeckel, et al.
Published: (2022-03-01)

Large-scale production of monoclonal antibodies in suspension culture /
by: 271860 Backer, M. P., et al.

Monoclonal antibodies : the second generation /
by: 186276 Zola, Heddy
Published: (1995)

Process scale purification of antibodies /
by: Gottschalk, Uwe
Published: (2009)

Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies
by: Brian A. Baldo
Published: (2022-02-01)

Monoclonal antibodies /
by: Peter, J. H., et al.
Published: (1992)